References
- JemalASiegelRWardEHaoYXuJThunMJCancer Statistics, 2009CA Cancer J Clin200959422524919474385
- HamiltonAHortobagyiGChemotherapy: what progress in the last 5 years?J Clin Oncol20052381760177515755984
- BollagDMMcQueneyPAZhuJEpothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of actionCancer Res19955511232523337757983
- GerthKBedorfNHofleGIrschikHReichenbachHEpothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological propertiesJ Antibiot (Tokyo)19964965605638698639
- LeeFYBorzilleriRFairchildCRBMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacyClin Cancer Res2001751429143711350914
- LeeFYBorzilleriRFairchildCRPreclinical discovery of ixabepilone, a highly active antineoplastic agentCancer Chemother Pharmacol200863115716618347795
- Boehnke MichaudLThe optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancerJ Oncol Pharm Pract20091529510619171553
- NettlesJHLiHCornettBKrahnJMSnyderJPDowningKHThe binding mode of epothilone A on alpha,beta-tubulin by electron crystallographyScience2004305568586686915297674
- LeeFYSmyklaRJohnstonKPreclinical efficacy spectrum and pharmacokinetics of ixabepiloneCancer Chemother Pharmacol200963220121218350296
- DumontetCJordanMALeeFFIxabepilone: targeting betaIII-tubulin expression in taxane-resistant malignanciesMol Cancer Ther200981172519139109
- RiveraELeeJDaviesAClinical development of ixabepilone and other epothilones in patients with advanced solid tumorsOncologist200813121207122319088324
- AwadaAPiccartMJJonesSFPhase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapyCancer Chemother Pharmacol200963341742518446338
- ManiSMcDaidHHamiltonAPhase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsClin Cancer Res20041041289129814977827
- GadgeelSMWozniakABoinpallyRRPhase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B designClin Cancer Res200511176233623916144926
- ShimizuTYamamotoNYamadaYPhase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumorsCancer Chemother Pharmacol200861575175817594093
- AghajanianCBurrisHA3rdJonesSPhase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomasJ Clin Oncol20072591082108817261851
- ZhuangSHAgrawalMEdgerlyMA phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 daysCancer200510391932193815800893
- AbrahamJAgrawalMBakkeSPhase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJ Clin Oncol20032191866187312721265
- DelfinoCCacciaGGonzalesLRGemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancerOncology2004661182315031594
- DemirayMKurtEEvrenselTPhase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposureCancer Invest200523538639116193637
- HensleyMLDizonDDerosaFA phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumorsInvest New Drugs200725433534117364235
- PlummerRWollPFyfeDA phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignanciesClin Cancer Res200814248288829419088046
- GoelSCohenMComezogluSNThe effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical developmentClin Cancer Res20081492701270918451235
- Ixempra (ixabepilone) intravenous infusion package insertSquibbBMPrinceton, NJBristol-Myers Squibb
- PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabineJ Clin Oncol200725233407341417606974
- OnitiloAAEngelJMGreenleeRTMukeshBNBreast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survivalClin Med Res200971–241319574486
- TalbotDCMoiseyenkoVVan BelleSRandomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclinesBr J Cancer20028691367137211986765
- PerezEAPaclitaxel in breast cancerOncologist19983637338910388129
- BonneterreJSpielmanMGuastallaJPEfficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experienceEur J Cancer199935101431143910673974
- TrudeauMEPhase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancerSemin Oncol1999263Suppl 8212610403470
- DegardinMBonneterreJHecquetBVinorelbine (navelbine) as a salvage treatment for advanced breast cancerAnn Oncol1994554234268075049
- IbrahimNKRahmanZValeroVPhase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinomaCancer19998671251125710506711
- ThomasETaberneroJFornierMPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancerJ Clin Oncol200725233399340617606975
- DenduluriNLowJALeeJJPhase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesJ Clin Oncol200725233421342717606971
- RocheHYelleLCognettiFPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyJ Clin Oncol200725233415342017606972
- MillerKDE2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancerClin Breast Cancer20033642142212636887
- GrayRBhattacharyaSBowdenCMillerKComisRLIndependent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerJ Clin Oncol200927304966497219720913
- CarverLASchnitzerJECaveolae: mining little caves for new cancer targetsNat Rev Cancer20033857158112894245
- DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res20061241317132416489089
- BunnellCVahdatLSchwartzbergLPhase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancerClin Breast Cancer20088323424118650153
- ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200725335210521717968020
- GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
- ThomasESIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol20082613222318445853
- BaselgaJZambettiMLlombart-CussacAPhase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJ Clin Oncol200927452653419075286
- LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol200624101633164216575015
- RugoHLyssAMoreno AspitiaAPhase III randomized study of paclitaxel versus paclitaxel albumin-stabilized nanoparticle formulation versus ixabepilone in combination with bevacizumab in patients with locally recurrent, stage IIIB or IV breast cancer2008 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=617539&version=HealthProfessional&protocolsearchid=7150845#Objectives_CDR0000617539Accessed October 20, 2009
- SchwartzbergLSTrial of dasatinib plus ixabepilone in 2nd or 3rd line metastatic breast cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=647959&version=HealthProfessional&protocolsearchid=7150845Accessed October 20, 2009
- YardleyDAPhase I/II Trial of sorafenib plus ixabepilone in Her2-negative metastatic breast cancer2009 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=633738&version=HealthProfessional&protocolsearchid=7150845Accessed October 20, 2009
- Karantza-WadsworthVPhase I/II study of ixabepilone and hydroxychloroquine in patients with taxane- and anthracycline-resistant metastatic breast cancer2008 http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=615000&version=HealthProfessional&protocolsearchid=7150845#ContactInfo_CDR0000615000Accessed October 20, 2009